Gerresheimer has completed its compliance and accounting review, received an unqualified audit opinion for 2025, and is now focused on selling Centor and refinancing debt. The restatement reduced 2024 revenue by €45 million and EBITDA by €31 million, while the company also booked €258 million in impairments mainly tied to development projects and the Chicago plant. 2025 revenue rose to €2.3 billion on the Bormioli Pharma acquisition, but organic growth was nearly flat and primary packaging glass remained weak. For 2026, Gerresheimer expects revenue in the lower half of its €2.3 billion to €2.4 billion range, an adjusted EBITDA margin of about 17% to 18%, and negative free cash flow before M&A of €50 million to €100 million.
Gerresheimer AGRestatement reduced prior revenue and EBITDA, impairments of €258M, and weak 2026 outlook with negative free cash flow.